Growth in health technology

Revenio Research Oy focuses on the development of the current products and on the health technology related research and development projects that aim to discover and commercialize new health technology related opportunities. The common nominators for these projects are screening, monitoring and worldwide need for cost savings in health care through preventive health care.

Our goal is to build growth paths from these new openings alongside the current products of Revenio Group.

Asthma is the most common chronic disease in children

More than 300 million people suffer from it. In Finland, 9.4 % of the population has asthma. Diagnosing asthma can be difficult, particularly in children. One in five children have asthma-like symptoms, and one in ten is diagnosed with asthma.

Diagnosing asthma is difficult, particularly in small children, and is based on the physician’s subjective viewpoint. The asthma product Ventica measures the expiratory flow of breathing as the child sleeps at night. These measurements detect changes in respiration that are typical of asthma, helping physicians to diagnose the condition and determine the optimal medication for it.

Revenio’s goal is to understand and demonstrate through studies how its asthma product Ventica® fits into physicians' current set of tools and patient treatment. There are no competing products which means that the market has to be created.

Reveniogroup research

Melanoma accounts for more than 30% of all new cancers

Skin cancers and their precursors are increasing rapidly throughout the world. The underlying cause of various skin changes lies in continuously increasing exposure to UV radiation. Some three million cases of skin cancer are diagnosed each year.

Revenio aims to launch an easy-to-use, mobile screening device that enables dermatologists to detect skin cancers and their precursors.

Revenio´s hyper-spectral camera recognizes the early stages of cancer and the borders of tumors that are invisible to the naked eye. This allows dermatologists more precise identification of the affected skin area and treatment follow-up. The hyper-spectral camera can see underneath a mole and indicate the depth and extent of skin that needs to be excised in order to fully remove the tumor and avoid repeat surgery. Currently approximately 50% of the cancer operations has to be repeated.